Novozymes Research and Development Expenses 2011-2023 | NVZMY

Novozymes research and development expenses for the twelve months ending December 31, 2023 were $0.293B, a 3.36% increase year-over-year.

  • Novozymes annual research and development expenses for 2023 were $0.293B, a 3.36% increase from 2022.
  • Novozymes annual research and development expenses for 2022 were $0.283B, a 11.35% decline from 2021.
  • Novozymes annual research and development expenses for 2021 were $0.32B, a 7.71% increase from 2020.

Novozymes Research and Development Expenses 2011-2023 | NVZMY

  • Novozymes annual research and development expenses for 2023 were $0.293B, a 3.36% increase from 2022.
  • Novozymes annual research and development expenses for 2022 were $0.283B, a 11.35% decline from 2021.
  • Novozymes annual research and development expenses for 2021 were $0.32B, a 7.71% increase from 2020.
Related Stocks
Company NameMarket
Cap
Linde (LIN)$225.2B
Ecolab (ECL)$71.3B
Givaudan SA (GVDNY)$49.5B
PPG Industries (PPG)$29.7B
Celanese (CE)$13.7B
Axalta Coating Systems (AXTA)$7.8B
Element Solutions (ESI)$6.2B
Balchem (BCPC)$5.6B
CSW Industrials (CSWI)$5.3B
NewMarket (NEU)$5.3B
Valvoline (VVV)$5.3B
Nissan Chemical (NNCHY)$4.5B
H B Fuller (FUL)$4.5B
Ashland (ASH)$4.3B
Sensient Technologies (SXT)$3.2B
Quaker Houghton (KWR)$3B
Arcadium Lithium (ALTM)$2.7B
Hawkins (HWKN)$2.5B
Minerals Technologies (MTX)$2.3B
Orbia Advance, S.A.B De C.V (MXCHY)$2B
Perimeter Solutions, SA (PRM)$1.8B
Ingevity (NGVT)$1.4B
ELEMENTIS (ELMTY)$1.3B
DAQO New Energy (DQ)$1.1B
Mativ Holdings (MATV)$1B
Orion S.A (OEC)$1B
Huabao Holdings (HUIHY)$943M
Green Plains (GPRE)$864M
Westlake Chemical Partners LP (WLKP)$781M
AdvanSix (ASIX)$763M